Corinne VENOT

Building the oncology strategy with Oncology management team (Marketing, Medical Affairs, R&D, Market Access) Deal making for early and late stage asset; Coordinating onco BD&L team Business deals: • Pieris (strategic research collaboration & License, aiming at generating IO bispecific products) • Vernalis (research collaboration & License on an undisclosed oncology target)

•Portfolio gap analysis, scouting and evaluation of oncology opportunities. Focus on opportunities at early stage: from target discovery until phase1. Leading scientific evaluation including Due Diligence. •Full involvement in deal making: Term sheet and Deal term negotiation, member of contract redaction team along with legal and Business Development •Main focus in discovery compounds and research collaboration •Responsible for ADC (Antibody Drug Conjugate) external partnering Business deals: •Dana Farber/Belfer Institute (strategic research collaboration, 3 years, aiming at identification of new target) •Ascenta (in-licensing of p53/mdm2 compound at candidate stage) •Oxford Biotherapeutics (in-licensing of Antibody products) •Algeta (research collaboration on Thorium RadioImmunoTherapy) •VUmc (Collaboration for radiolabelled imaging antibodies) •IMODI (French consortium for PDX models) •AVIESAN/Copio, financing of Specific project (Target identification) •Avipep, Catalent, Innate Pharma, Glykos (research collaboration agreements to develop ADC next generation) °Innate Pharma, NKCellEngager research collaboration and license agreement •12 other undisclosed deals

•Project team leader from screening to preclinical phase. •New targets identification, nomination of 5 new projects in oncology portfolio. •Coordination of a task force on a new target family (Tyrosine phosphatase). Task force was involving biologists from oncology and diabetes, chemists, drug designers. Coordination between 3 R&D sites. •Project team member (for antibody) and leader (for small molecule) on IGF1R program, covering coordination of matrix team work, establishment and follow-up of preclinical strategy, working on responder patient profile for clinic. •Management of external collaborations aiming at IGF1R compounds characterization (Nantes University, IGR and St Antoine Hospital) and consultant on program strategy (M. Pollak from McGill Univ)

(6 months) Training period: Product manager’s assistant (Pyostacine) (6 months) Product manager in charge of Customer Care Strategy •Elaboration of a training session for physicians •Realization, coordination and follow-up of a Customer Care strategy

Thesis and Master Degree in biology •Communication inside and outside the company (French/English) •Writing publications (French/English)